 |
| Anno I | Numero 6 | Ottobre 2016 |
| Comitato scientifico editoriale: Paolo A. Ascierto, Vanna Chiarion-Sileni Editore: Intermedia – Direttore Responsabile: Mauro Boldrini |
| Notizie dalla ricerca |
| Clinical outcomes in metastatic uveal melanoma treated with PD-1 and PD-L1 antibodies |
| Antibodies inhibiting the programmed death receptor 1 (PD-1) have demonstrated significant activity in the treatment of advanced cutaneous melanoma. The efficacy and safety of PD-1 blockade in patients with uveal melanoma has not been well characterized. Fifty-eight patients with stage IV uveal melanoma received PD-1 or PD-1 ligand (PD-L1) antibodies between 2009 and 2015 at 9 academic centers. Patients who were evaluable for response were eligible for the analysis. Imaging was … |
| Continua a leggere |
| Molecular and epigenetic features of melanomas and tumor immune microenvironment linked to durable remission to ipilimumab-based immunotherapy in metastatic patients |
| Ipilimumab (Ipi) improves the survival of advanced melanoma patients with an incremental long-term benefit in 10-15% of patients. A tumor signature that correlates with this survival benefit could help optimizing individualized treatment strategies. Freshly frozen melanoma metastases were collected from patients treated with either Ipi alone (n: 7) or Ipi combined with a dendritic cell vaccine (TriMixDC-MEL) (n: 11). Samples were profiled by immunohistochemistry (IHC), whole … |
| Continua a leggere |
| The efficacy of anti-PD-1 agents in acral and mucosal melanoma |
| Therapeutic antibodies against programmed cell death receptor 1 (PD-1) are considered front-line therapy in metastatic melanoma. The efficacy of PD-1 blockade for patients with biologically distinct melanomas arising from acral and mucosal surfaces has not been well described. A multi-institutional, retrospective cohort analysis identified adults with advanced acral and mucosal melanoma who received treatment with nivolumab or pembrolizumab as standard clinical practice through … |
| Continua a leggere |
| Immune checkpoint blockade with concurrent electrochemotherapy in advanced melanoma: a retrospective multicenter analysis |
| Growing evidence suggests that concurrent loco-regional and systemic treatment modalities may lead to synergistic anti-tumor effects in advanced melanoma. In this retrospective multicenter study, we evaluate the use of electrochemotherapy (ECT) combined with ipilimumab or PD-1 inhibition. We investigated patients with unresectable or metastatic melanoma who received the combination of ECT and immune checkpoint blockade for distant or cutaneous metastases within 4 weeks. Clinical and … |
| Continua a leggere |
| Association of Pembrolizumab With Tumor Response and Survival Among Patients With Advanced Melanoma |
| The programmed death 1 (PD-1) pathway limits immune responses to melanoma and can be blocked with the humanized anti-PD-1 monoclonal antibody pembrolizumab. To characterize the association of pembrolizumab with tumor response and overall survival among patients with advanced melanoma. Open-label, multicohort, phase 1b clinical trials (enrollment, December 2011-September 2013). Median duration of follow-up was 21 months. The study was performed in academic … |
| Continua a leggere |
| Appuntamenti AIOM |
| XVIII CONGRESSO NAZIONALE AIOM |
| Roma, 28 – 30 ottobre 2016 |
| Link all'evento |
| MICRO-AMBIENTE TUMORALE. Antiangiogenici e immunoterapia: miti e realtà |
| Milano, 11 ottobre 2016 |
| XIV NIBIT Meeting CANCER BIO – Immunotherapy in Siena |
| Siena, 13 – 15 ottobre 2016 |
| DIALOGHI SULL'IMMUNOTERAPIA DEI TUMORI DELL'AIOM CAMPANIA |
| Benevento, 18 ottobre 2016 Napoli, 20 ottobre 2016 |
| 4th International Conference TRANSLATIONAL RESEARCH IN ONCOLOGY |
| Meldola (FC), 8 novembre 2016 Forlì, 9 – 11 novembre 2016 |
| NUOVE FRONTIERE DIAGNOSTICO-TERAPEUTICHE NELLE NEOPLASIE POLMONARI, RENALI E NEL MELANOMA |
| Varese, 12 novembre 2016 |
| XXII CONGRESSO NAZIONALE IMI – Intergruppo Melanoma Italiano Multidisciplinarità e integrazione intorno al paziente |
| Ragusa, 13 – 15 novembre 2016 |
| First International Congress CLINICAL NEEDS AND TRANSLATIONAL RESEARCH IN ONCOLOGY |
| Reggio Emilia, 28 – 29 novembre 2016 |
| MELANOMA BRIDGE 2016 |
| Napoli, 30 novembre – 3 dicembre 2016 |
| IMMUNOTHERAPY BRIDGE 2016 |
| Napoli, 30 novembre 2016 |
| Questi e altri appuntamenti si possono consultare sul sito AIOM www.aiom.it |
| Editore: Intermedia s.r.l. – Via Malta 12/b, 25124 Brescia – tel. 030 226105 fax 030 2420472 – Reg. Trib. di Brescia n. 35/2001 del 2/7/2001 Per contattare la redazione e commentare le notizie clicca qui: redazione Per consultare i numeri arretrati della newsletter clicca qui: archivio Per sospendere la ricezione di questa newsletter clicca qui: AIOM news RIMUOVI |
Questo progetto è stato realizzato con il contributo di  |